Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.

Wan L, Chen M, Cao J, Dai X, Yin Q, Zhang J, Song SJ, Lu Y, Liu J, Inuzuka H, Katon JM, Berry K, Fung J, Ng C, Liu P, Song MS, Xue L, Bronson RT, Kirschner MW, Cui R, Pandolfi PP, Wei W.

Cancer Discov. 2017 Apr;7(4):424-441. doi: 10.1158/2159-8290.CD-16-0647. Epub 2017 Feb 7.

PMID:
28174173
2.

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Tate SC, Burke TF, Hartman D, Kulanthaivel P, Beckmann RP, Cronier DM.

Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.

3.

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L.

Oncotarget. 2016 Apr 12;7(15):19997-20015. doi: 10.18632/oncotarget.7671.

4.

The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Webster MR, Kugel CH 3rd, Weeraratna AT.

Biochim Biophys Acta. 2015 Dec;1856(2):244-51. doi: 10.1016/j.bbcan.2015.10.002. Epub 2015 Nov 4. Review.

5.

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

Prasad CP, Mohapatra P, Andersson T.

Cancers (Basel). 2015 Sep 17;7(3):1900-24. doi: 10.3390/cancers7030868. Review.

6.

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.

Parker R, Vella LJ, Xavier D, Amirkhani A, Parker J, Cebon J, Molloy MP.

Front Oncol. 2015 May 15;5:95. doi: 10.3389/fonc.2015.00095. eCollection 2015.

7.

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.

Wellbrock C, Arozarena I.

Pigment Cell Melanoma Res. 2015 Jul;28(4):390-406. doi: 10.1111/pcmr.12370. Epub 2015 Apr 17. Review.

8.

Genotyping of cutaneous melanoma.

Glitza IC, Davies MA.

Chin Clin Oncol. 2014 Sep;3(3):27.

9.

Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Udager AM, Pan J, Magers MJ, Palapattu GS, Morgan TM, Montgomery JS, Weizer AZ, Hafez KS, Miller DC, Wolf JS Jr, McHugh JB, Chinnaiyan AM, Dhanasekaran SM, Mehra R.

Am J Surg Pathol. 2015 Apr;39(4):549-57. doi: 10.1097/PAS.0000000000000377.

10.

Melanoma brain colonization involves the emergence of a brain-adaptive phenotype.

Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E.

Oncoscience. 2014 Jan 10;1(1):82-94. eCollection 2014.

11.

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ.

PLoS One. 2014 Jul 1;9(7):e101286. doi: 10.1371/journal.pone.0101286. eCollection 2014.

12.

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.

13.

The GIST of targeted therapy for malignant melanoma.

Bello DM, Dematteo RP, Ariyan CE.

Ann Surg Oncol. 2014 Jun;21(6):2059-67. doi: 10.1245/s10434-013-3373-z. Epub 2014 Feb 15. Review.

14.

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J.

PLoS One. 2013 Aug 30;8(8):e72692. doi: 10.1371/journal.pone.0072692. eCollection 2013.

15.

MC1R is a potent regulator of PTEN after UV exposure in melanocytes.

Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R.

Mol Cell. 2013 Aug 22;51(4):409-22. doi: 10.1016/j.molcel.2013.08.010.

16.

Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Fernández-Pérez MP, Montenegro MF, Sáez-Ayala M, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

Neoplasia. 2013 Jul;15(7):826-39.

17.

Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs.

Montrose K, Yang Y, Sun X, Wiles S, Krissansen GW.

Sci Rep. 2013;3:1661. doi: 10.1038/srep01661.

18.

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.

Clin Cancer Res. 2013 May 15;19(10):2688-98. doi: 10.1158/1078-0432.CCR-12-2556. Epub 2013 Apr 2. Erratum in: Clin Cancer Res. 2013 Jul 15;19(14):4018.

19.

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110. Epub 2013 Feb 27.

Supplemental Content

Support Center